Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.86 billion. The enterprise value is $1.55 billion.
Important Dates
The last earnings date was Monday, March 2, 2026, before market open.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 73.75 million shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | 73.75M |
| Shares Outstanding | 73.75M |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.58% |
| Owned by Insiders (%) | 1.29% |
| Owned by Institutions (%) | 55.40% |
| Float | 72.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.51 |
| PS Ratio | 17.02 |
| Forward PS | 15.40 |
| PB Ratio | 6.80 |
| P/TBV Ratio | 7.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.88, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.88 |
| Quick Ratio | 5.52 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.72% and return on invested capital (ROIC) is -127.65%.
| Return on Equity (ROE) | -26.72% |
| Return on Assets (ROA) | -14.29% |
| Return on Invested Capital (ROIC) | -127.65% |
| Return on Capital Employed (ROCE) | -30.42% |
| Weighted Average Cost of Capital (WACC) | 11.17% |
| Revenue Per Employee | $402,909 |
| Profits Per Employee | -$308,479 |
| Employee Count | 263 |
| Asset Turnover | 0.26 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $1.38 million in taxes.
| Income Tax | 1.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +96.23% in the last 52 weeks. The beta is 1.28, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | +96.23% |
| 50-Day Moving Average | 24.00 |
| 200-Day Moving Average | 18.32 |
| Relative Strength Index (RSI) | 62.04 |
| Average Volume (20 Days) | 561,388 |
Short Selling Information
The latest short interest is 3.97 million, so 5.39% of the outstanding shares have been sold short.
| Short Interest | 3.97M |
| Short Previous Month | 3.78M |
| Short % of Shares Out | 5.39% |
| Short % of Float | 5.46% |
| Short Ratio (days to cover) | 6.06 |
Income Statement
In the last 12 months, Zymeworks had revenue of $105.97 million and -$81.13 million in losses. Loss per share was -$1.08.
| Revenue | 105.97M |
| Gross Profit | -31.04M |
| Operating Income | -92.55M |
| Pretax Income | -79.75M |
| Net Income | -81.13M |
| EBITDA | -84.82M |
| EBIT | -92.55M |
| Loss Per Share | -$1.08 |
Full Income StatementBalance Sheet
The company has $228.80 million in cash and $18.27 million in debt, with a net cash position of $252.32 million or $3.42 per share.
| Cash & Cash Equivalents | 228.80M |
| Total Debt | 18.27M |
| Net Cash | 252.32M |
| Net Cash Per Share | $3.42 |
| Equity (Book Value) | 268.50M |
| Book Value Per Share | 3.60 |
| Working Capital | 206.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.01 million and capital expenditures -$1.52 million, giving a free cash flow of -$34.53 million.
| Operating Cash Flow | -33.01M |
| Capital Expenditures | -1.52M |
| Free Cash Flow | -34.53M |
| FCF Per Share | -$0.47 |
Full Cash Flow StatementMargins
Gross margin is -29.29%, with operating and profit margins of -87.34% and -76.56%.
| Gross Margin | -29.29% |
| Operating Margin | -87.34% |
| Pretax Margin | -75.26% |
| Profit Margin | -76.56% |
| EBITDA Margin | -80.05% |
| EBIT Margin | -87.34% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.61% |
| Shareholder Yield | 0.61% |
| Earnings Yield | -4.50% |
| FCF Yield | -1.91% |
Analyst Forecast
The average price target for Zymeworks is $36.33, which is 44.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.33 |
| Price Target Difference | 44.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 32.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 4.95 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.95 |
| Piotroski F-Score | 4 |
